Mammography Screening Indications
Mammography screening should begin at age 40 years with annual screening for women at intermediate risk, and continue as long as the woman is in good health with reasonable life expectancy. 1
Age-Based Screening Recommendations
Women Ages 40-49 Years
- Annual screening mammography should begin no later than age 40 for women at intermediate (average) risk 1
- This represents the most current evidence-based approach, as mortality reduction is significantly greater when screening begins at 40 rather than 45 or 50 years of age 1
- The 2025 ACR guidelines supersede older 2009 USPSTF recommendations that recommended against routine screening in this age group 2
Women Ages 50-74 Years
- Annual screening mammography is recommended 1
- This age group shows the strongest mortality reduction benefit from screening
- Both biennial and annual screening reduce mortality, but annual screening provides greater benefit 1
Women Ages 75 and Older
- Continue screening based on life expectancy and overall health status rather than age alone 1
- Women should continue as long as they remain in good health and are willing to undergo examination and subsequent testing if abnormalities are identified 1
- Screening recommendations should be based on life expectancy and competing comorbidities, as mortality reduction requires years to be fully attained 1
High-Risk Populations Requiring Earlier or More Intensive Screening
Family History of Breast Cancer
- Begin screening 10 years prior to the youngest age at presentation in the family, but generally not before age 30 1
- Example: If mother diagnosed at age 38, begin screening at age 28
Personal History of High-Risk Lesions
- Women with lobular neoplasia or atypical hyperplasia diagnosed before age 40 should begin annual screening at time of diagnosis, but generally not before age 30 1
Personal History of Breast Cancer
- Annual mammography for surveillance following breast conservation therapy 1
- Early detection of second breast cancers improves survival
Screening Modality
Digital breast tomosynthesis (DBT) or standard digital mammography are both appropriate 1
- DBT increases cancer detection rate by 1.6-3.2 per 1,000 examinations compared to digital mammography
- DBT decreases recall rates by 2.2% compared to digital mammography 1
Key Evidence Supporting These Recommendations
The evidence base demonstrates:
- At least 22% reduction in breast cancer mortality from screening mammography across multiple randomized controlled trials 1
- 27-31% mortality reduction demonstrated in the Swedish Two-County trial after 29 years of follow-up 1
- Observational studies show ≥40% mortality reduction in women who were actually screened 1
- Screen-detected tumors are typically lower stage, smaller, and more likely to be node-negative, reducing treatment morbidity 1
Common Pitfalls to Avoid
- Do not delay screening until age 50 in average-risk women—this misses the mortality benefit of earlier detection 1
- Do not stop screening at an arbitrary age cutoff like 75—base decisions on health status and life expectancy 1
- Do not forget to screen earlier in women with family history—the 10-year rule is critical 1
- Approximately 10% of screening mammograms result in recall, but less than 2% result in biopsy recommendation—this should not deter appropriate screening 1